Pfizer board approves marketing, supply pact with Mylan for two brands

Pfizer Ltd's board has approved a five-year marketing and supply agreement with Mylan Pharmaceuticals for the brands Ativan and Pacitane, targeting the treatment of anxiety disorders and Parkinsonism. The partnership leverages Mylan's expertise in the central nervous system therapy area to enhance product distribution and engagement with neurologists and psychiatrists in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zTsG1bv
via IFTTT